PreDiction and Validation of Clinical CoursE of Coronary Artery DiSease With CT-Derived Non-Invasive HemodYnamic Phenotyping and Plaque Characterization (DESTINY Study)

Sponsor
Samsung Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04794868
Collaborator
Elucid Bioimaging Inc. (Industry), Shanghai Institute of Cardiovascular Diseases (Other)
356
2
32
178
5.6

Study Details

Study Description

Brief Summary

Acute coronary syndrome (ACS) and sudden cardiac death can be the first manifestation of coronary artery disease and are the leading cause of death in the majority of the world's population. The main pathophysiology of ACS is well-known and fibrous cap thickness, presence of a lipid core, and the degree of inflammation have been proposed as the key determinants of plaque vulnerability. Previous studies using virtual histology intravascular ultrasound or optical coherence tomography showed that clinical application of this concept improved risk prediction of ACS. However, these approaches have not been widely adopted in daily practice due to relatively low positive predictive values, low prevalence of high-risk plaques and the invasive nature of diagnostic modalities.

Non-invasive imaging studies with coronary computed tomography angiography (CCTA) also showed the clinical value of CCTA-derived high risk plaque characteristics (HRPC). In addition, the recent progress in CCTA and computational fluid dynamics (CFD) technologies enables simultaneous assessment of anatomical lesion severity, presence of HRPC and quantification of hemodynamic forces acting on plaques in patient-specific geometric models. As plaque rupture is a complicated biomechanical process influenced by the structure and constituents of the plaque as well as the external mechanical and hemodynamic forces acting on the plaque, a comprehensive evaluation of lesion geometry, plaque characteristics and hemodynamic parameters may enhance the identification of high-risk plaque and the prediction of ACS risk.

In this regard, the current study is designed to evaluate prognostic implications of comprehensive non-invasive hemodynamic assessment using CCTA and CFD in the identification of high risk plaques that caused subsequent ACS.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: CCTA-derived high risk plaque characteristics
  • Diagnostic Test: CFD-derived hemodynamic parameters

Detailed Description

The study population was collected from Samsung Medical Center. Target population is patients who suffered a clearly documented ACS (acute myocardial infarction [MI] or unstable angina with objective evidence of plaque rupture) or those who underwent significant lesion progression in angiography and treated by percutaneous coronary intervention (PCI) and had undergone CCTA from 6 months to 3 years prior to the coronary events.

CCTA images were screened for plaque characteristics and CFD analysis at core laboratories in Elucid Bioimaging, Inc, MA, USA and Shanghai Institute of Cardiovascular Diseases, Shanghai, China, respectively. Lesions with diameter stenosis (DS) > 30% based on CCTA evaluation were included analysis. The presence of conventional CCTA-HRPC (minimum lumen area<<4 mm2, plaque burden≥70%, low-attenuation plaque, positive remodeling, napkin-ring sign, and spotty calcification) and parameters from tissue characterization using VascuCAP software will be assessed in each lesion by an independent observer blinded to the clinical data and CFD results. The hemodynamic parameters from CFD will include 1) per-vessel FFR derived from CCTA (FFRCT); 2) change in FFRCT across the lesion (△FFRCT); 3) FFRCT pullback pressure gradient (PPG) index (FFRCT-PPG index); 4) Fractional myocardial mass (FMM) of the target stenosis.

Using the occurrence of ACS or PCI for the progressed lesion as clinical endpoint, prognostic implications of CCTA-derived HRPC or hemodynamic parameters will be analyzed.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
356 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Prediction and Validation of Clinical Course of Coronary Artery Disease With CT-Derived Non-Invasive Hemodynamic Phenotyping and Plaque Characterization
Actual Study Start Date :
Apr 1, 2020
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Culprit vessel of acute coronary syndrome

Culprit vessel of acute coronary syndrome

Diagnostic Test: CCTA-derived high risk plaque characteristics
Presence of CCTA-derived high risk plaque characteristics

Diagnostic Test: CFD-derived hemodynamic parameters
CFD-derived hemodynamic parameters

Non-culprit vessel of acute coronary syndrome

Non-culprit vessel of acute coronary syndrome

Diagnostic Test: CCTA-derived high risk plaque characteristics
Presence of CCTA-derived high risk plaque characteristics

Diagnostic Test: CFD-derived hemodynamic parameters
CFD-derived hemodynamic parameters

Outcome Measures

Primary Outcome Measures

  1. Acute myocardial infarction [3 years after index CCTA]

    Target vessel-related acute myocardial infarction

  2. Revascularization [3 years after index CCTA]

    Target vessel-related revsacularization

Secondary Outcome Measures

  1. Target vessel failure [3 years after index CCTA]

    A composite of Cardiac death, Target vessel-related acute myocardial infarction, Target vessel-related revsacularization

  2. All-cause death [3 years after index CCTA]

    All-cause death

  3. Cardiac death [3 years after index CCTA]

    Death due to cardiac cause

  4. Major adverse cardiac and cerebral events [3 years after index CCTA]

    A composite of All-cause death, Target vessel-related acute myocardial infarction, Target vessel-related revsacularization, Cerebrovascular accident

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients who presented with ACS and underwent invasive coronary angiography with identifiable culprit lesion

  2. Patients who presented with stable ischemic heart disease and underwent invasive coronary angiography for the significant epicardial coronary stenosis

  3. The patients who underwent coronary CT angiography, regardless of the reason (for example, routine healthcare check-up, or evaluation for stable angina or atypical chest pain) prior to the acute event.

  4. Time limit of CCTA: 6 months ~ 3 years prior to the event.

  5. Definition of ACS:

  • The patients with acute myocardial infarction should meet one of the following criteria;

  • Cardiac enzyme elevation "and"

  • Identified culprit lesion confirmed by invasive coronary angiography, IVUS, or OCT

  • The patients with unstable angina should be accompanied by the evidence of plaque rupture confirmed with invasive coronary angiography, IVUS, or OCT

Exclusion Criteria:

Exclusion criteria for Patient enrollment

  • Patients with acute coronary syndrome without clear evidence of culprit lesion

  • Patients with stents in two or more vessel territories prior to CCTA

  • Poor quality of CCTA which is unsuitable for plaque and CFD analysis

  • Patients with ACS culprit lesion in a stented vessel

  • Patients with previous history of coronary artery bypass graft surgery

  • Secondary myocardial infarction due to other general medical conditions, such as sepsis, arrhythmia, bleeding, etc.

  • Poor quality CCTA images unsuitable for CFD analysis

  • No available unprocessed CCTA data

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shanghai Institute of Cardiovascular Diseases Shanghai China
2 Samsung Medical Center Seoul Korea, Republic of 06351

Sponsors and Collaborators

  • Samsung Medical Center
  • Elucid Bioimaging Inc.
  • Shanghai Institute of Cardiovascular Diseases

Investigators

  • Principal Investigator: Joo Myung Lee, MD, MPH, PhD, Samsung Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Joo Myung Lee, Assistant Professor, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT04794868
Other Study ID Numbers:
  • NCT20210308-JM
First Posted:
Mar 12, 2021
Last Update Posted:
Jul 29, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Joo Myung Lee, Assistant Professor, Samsung Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2021